KRAS and cancer: Many discordant mutations found are in important oncogenes such as APC (R1676T), JAK1 (860–861,-/X), PIK3CA (H1047R) , KRAS (A59T), BRCA1 (1856Q, Y856H), EGFR (R574W), MPL (R229T) ,NF1 (D2077A), RET (D58N) and TP53 (S241C, Q331*) highlighting the effectiveness of the developed cfDNA assay to monitor potential emergent cancer alterations directly from cfDNA, even when mutation-bearing molecules are very rare in plasma.